Summary of the Conference Call Transcript Industry Overview - **Industry Focus**: Edible Mushroom Industry and Cordyceps Sinensis (冬虫夏草) - **Market Growth**: The edible mushroom industry is experiencing a continuous growth trend, with a projected compound annual growth rate (CAGR) of 6.0% from 2019 to 2024 according to the China Edible Mushroom Association [1] Key Insights on Cordyceps Sinensis - **Demand and Supply Dynamics**: There is a sustained increase in demand for Cordyceps Sinensis, with product forms becoming more diverse. Conversely, the supply of wild Cordyceps is declining, while large-scale artificial cultivation is advancing. This may lead to long-term price increases or strong fluctuations [1] - **Policy Support**: Government policies are encouraging the research and cultivation of endangered medicinal materials and the development of substitutes. Continuous technological advancements in artificial cultivation are being made [1] - **Company Initiatives**: Several companies are strategically positioning themselves in the market. For instance, Dongyangguang has an annual production capacity exceeding 60 tons, while Zhongxing Junye is developing factory-based cultivation projects, showing positive profit trends. Xue Rong Biological is accumulating technology for artificial cultivation of Cordyceps Sinensis [1] Insights on the Edible Mushroom Industry - **Market Structure**: The industry is optimizing its market structure, with production capacity returning to rational levels. Leading companies like Zhongxing Junye maintain over 40% market share and a gross margin exceeding 30% [5] - **Price Stabilization**: Prices for various mushroom types, including Enoki mushrooms and Pleurotus eryngii, are stabilizing at the bottom due to supply adjustments by leading companies like Xue Rong Biological and Zhongxing Junye, which are reducing production capacity to alleviate supply pressure [2][3][7] - **Profitability**: The profitability of the double mushroom segment remains stable, supported by sufficient supply and demand driven by the restaurant sector [6][3] Investment Recommendations - **Edible Mushroom Sector**: As companies reduce capital expenditures and production capacity, supply pressure is expected to ease, leading to potential price stabilization and upward movement. Leading enterprises are positioned to improve profitability due to their advantages in scale, technology, and management [8] - **Cordyceps Sinensis Sector**: With rising health awareness, improving policies, and mature artificial cultivation technologies, the artificial cultivation of Cordyceps Sinensis is entering a phase of large-scale industrial development. Companies with forward-looking capacity and technological layouts are expected to show greater growth potential [8] - **Key Companies**: Zhongxing Junye and Xue Rong Biological are highlighted as significant players in the industry [8] Risk Factors - **Market Competition**: Increased competition in the market poses a risk [9] - **Food Safety**: Potential food safety risks could impact the industry [9] - **Innovation Risks**: Risks associated with research and development not meeting expectations [9] - **Raw Material Costs**: Rising costs of raw materials present a financial risk [9]

Investment Rating - The report assigns an investment rating of "Positive" for the industry, marking it as the first rating issued [2]. Core Insights - The edible fungus industry is experiencing growth, with a projected compound annual growth rate (CAGR) of 6.0% for the national edible fungus output value from 2019 to 2024. The market structure is optimizing as production capacity returns to rational levels [5][6]. - The demand for Cordyceps sinensis is increasing due to its various health benefits, and the supply is becoming scarcer due to overharvesting and climate change. This is expected to lead to long-term price increases or strong fluctuations [5][6]. - The report highlights the ongoing technological advancements and policy improvements that are creating new opportunities for the artificial cultivation of Cordyceps sinensis, which is transitioning into a rapid industrialization phase [5][6]. Summary by Sections 1. Cordyceps Sinensis: Continuous Advancement in Large-Scale Artificial Cultivation - The industry chain for Cordyceps sinensis is continuously improving, with applications expanding across pharmaceuticals, health products, and cosmetics [5][9]. - The price of wild Cordyceps sinensis is expected to remain strong due to its increasing scarcity, with prices returning to 210,000-220,000 yuan per kilogram in 2023 [5][28]. - Policies are being implemented to ensure sustainable harvesting and scientific protection of Cordyceps sinensis, promoting the development of artificial cultivation [5][30]. 2. Edible Fungi: Market Structure Optimization and Rational Return of Production Capacity - The edible fungus industry is witnessing stable growth, with the production of enoki mushrooms stabilizing at over 5,300 tons per day in 2023, and the price is expected to recover from its bottom [5][6]. - The production of button mushrooms is stable, with a daily output of 867 tons in 2023, and leading companies maintain a high market share [5][6]. - The demand for king oyster mushrooms is also improving, supported by household consumption and high-end dining, with industrial production reaching 349 tons per day in 2023 [5][6]. 3. Investment Recommendations - The report suggests that the edible fungus industry will see price stabilization and upward movement due to reduced supply pressure from capital expenditure and capacity cuts by enterprises [5][6]. - In the Cordyceps sinensis sector, companies with advanced capacity and technological layouts are expected to show greater growth potential as health awareness increases [5][6].

Core Viewpoint - The planting industry sector experienced a rise of 2.94% on January 29, with Hainan Rubber leading the gains, while the Shanghai Composite Index closed at 4157.98, up 0.16%, and the Shenzhen Component Index closed at 14300.08, down 0.3% [1]. Group 1: Stock Performance - Hainan Rubber (601118) closed at 7.84, up 9.96%, with a trading volume of 2.3481 million shares and a transaction value of 1.772 billion [1]. - Shennong Seed Industry (300189) closed at 7.67, up 8.33%, with a trading volume of 3.3919 million shares and a transaction value of 2.561 billion [1]. - Qiule Seed Industry (920087) closed at 19.08, up 7.31%, with a trading volume of 189,600 shares and a transaction value of 354 million [1]. - Other notable stocks include Nongfa Seed Industry (600313) at 8.03, up 6.36%, and Kangnong Seed Industry (920403) at 27.14, up 3.39% [1]. Group 2: Capital Flow - The planting industry sector saw a net outflow of 229 million from institutional investors, while retail investors contributed a net inflow of 97.6117 million [2]. - Major stocks like Hainan Rubber had a net inflow of 1.62 billion from institutional investors, but a net outflow of 214.089 million from speculative funds [3]. - Shennong Seed Industry experienced a net inflow of 14.4615 million from institutional investors, while facing a net outflow of 1.80467 million from speculative funds [3].

Group 1 - The core point of the news is that Zhongxing Junye's stock price dropped by 5% to 15.76 CNY per share, with a trading volume of 162 million CNY and a turnover rate of 2.57%, resulting in a total market capitalization of 6.197 billion CNY [1] - Zhongxing Junye, established on November 18, 2005, and listed on June 26, 2015, is primarily engaged in the research, industrial cultivation, and sales of edible mushrooms [1] - The company's main revenue sources are: 63.04% from Agaricus bisporus, 35.32% from Enoki mushrooms, 0.89% from Cordyceps, 0.53% from ecological breeding of Cordyceps sinensis, and 0.22% from other products [1] Group 2 - Manulife Fund's Manulife Consumer Dividend Index A (008928) is among the top ten circulating shareholders of Zhongxing Junye, having increased its holdings by 363,100 shares to a total of 3.498 million shares, representing 0.9% of the circulating shares [2] - The fund has incurred an estimated floating loss of approximately 2.9033 million CNY today [2] - The fund was established on March 26, 2020, with a current size of 720 million CNY, and has a year-to-date return of 0.21%, ranking 5031 out of 5551 in its category [2] Group 3 - The fund manager of Manulife Consumer Dividend Index A is Li Tingting, who has been in the position for 4 years and 33 days, managing total assets of 2.322 billion CNY [3] - During her tenure, the best fund return was 46.22%, while the worst return was -35.89% [3] Group 4 - In the fourth quarter, Manulife Consumer Dividend Index A reduced its holdings in Zhongxing Junye by 1.269 million shares, bringing the total to 2.229 million shares, which constitutes 2.84% of the fund's net value, making it the fifth-largest holding [4] - The estimated floating loss for the fund today is approximately 1.8501 million CNY [4]

天水众兴菌业科技股份有限公司 关于使用部分闲置自有资金进行委托理财的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 天水众兴菌业科技股份有限公司（以下简称"公司"）于 2025 年 03 月 21 日召开第五届董事会第十次会议审议通过了《关于使用部分闲置自有资金进行委 托理财的议案》，同意公司（包括控股子公司，下同）在确保不影响正常运营和 资金安全的前提下，使用不超过 60,000 万元（含 60,000 万元，下同）闲置自有 资金（含截至董事会召开日未赎回的委托理财产品金额，下同）进行委托理财， 额度使用期限自董事会审议通过之日起 12 个月内。在额度和有效期内资金可以 滚动使用，期限内任一时点的委托理财金额（含前述投资的收益进行再投资的相 关金额）不得超过 60,000 万元。公司董事会授权公司经营管理层行使投资决策 权并签署相关文件。《关于使用部分闲置自有资金进行委托理财的公告》（公告 编号：2025-016）详见 2025 年 03 月 22 日公司指定信息披露媒体《证券时报》、 《中国证券报》及巨潮资讯网（http://www.cninfo ...

众兴菌业今日上涨2.80%，全天换手率8.65%，成交额5.43亿元，振幅19.58%。龙虎榜数据显示，机构净 买入3534.72万元，营业部席位合计净卖出824.85万元。 | 买/卖 | | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | --- | | 买一 | 机构专用 | | 2699.72 | 733.57 | | 买二 | 机构专用 | | 1869.38 | 1140.31 | | 买三 | 机构专用 | | 1744.75 | 0.00 | | 买四 | 机构专用 | | 1097.65 | 1137.64 | | 买五 | 机构专用 | | 1031.78 | 1285.25 | | 卖一 | 机构专用 | | 919.44 | 1531.23 | | 卖二 | 机构专用 | | 1031.78 | 1285.25 | | 卖三 | 机构专用 | | 1869.38 | 1140.31 | | 卖四 | 机构专用 | | 1097.65 | 1137.64 | | 卖五 | | 长江证券股份有限公司宜昌沿江大道证券营业部 ...

Core Viewpoint - The company focuses on the research, industrial cultivation, and sales of edible and medicinal mushrooms, such as enoki and Agaricus bisporus, while also engaging in a land use rights project through a bidding process in Tianshui City [1]. Group 1: Business Operations - The main business of the company includes the development, factory cultivation, and sales of edible and medicinal mushrooms [1]. - The company emphasizes enhancing its profitability to provide better returns for investors [1]. Group 2: Strategic Development - The company’s subsidiary, Tianshui Yusheng Real Estate Co., Ltd., acquired land use rights through participation in a bidding project related to urban renewal financing in Tianshui City [1]. - The company plans to advance this project opportunistically, considering market cycles and its development strategy, without impacting its core business [1].

Group 1 - Company Sanwei Communication announced a partnership to establish a private equity fund with a total investment of 114 million yuan, with the company contributing 25 million yuan, focusing on high-tech industries such as smart manufacturing and new energy [1] - Zijin Mining plans to acquire 100% of Allied Gold Corporation for approximately 280 billion yuan, with core assets including gold mines in Mali and Ivory Coast, and an expected increase in gold production to 25 tons by 2029 [2] - Haike New Source signed a long-term cooperation agreement with BYD Lithium Battery to supply at least 100,000 tons of solvents annually for three years [3] Group 2 - China Aluminum International reported a new contract total of 468.36 billion yuan for 2025, a year-on-year increase of 51.94%, with significant growth in industrial and overseas contracts [4] - Jianxin Co. expects a net loss of 20 to 29 million yuan for 2025, compared to a profit of 19.37 million yuan in the previous year [5] - ST Dongjing anticipates a loss of 40 to 60 million yuan for 2025, an improvement from a loss of 73.45 million yuan in the previous year [6] Group 3 - Zhejiang Haideman plans to raise up to 1.517 billion yuan through a private placement for high-end machine tool projects [7] - Anlu Technology intends to raise up to 1.262 billion yuan for FPGA chip development projects [8][9] - AVIC Chengfei expects a net profit increase of 5.47% to 11.67% for 2025, projecting profits between 3.4 billion and 3.6 billion yuan [10] Group 4 - Hengtong Technology forecasts a net profit increase of 82.95% to 110.05% for 2025, with expected profits between 270 million and 310 million yuan [11] - Qingmu Technology anticipates a net profit increase of 30% to 50% for 2025, projecting profits between 118 million and 136 million yuan [13] - Zhongke Microelectronics expects a loss of 18 to 25 million yuan for 2025, marking a shift from profit to loss [14] Group 5 - Huashan Electric predicts a loss of 42 to 49.2 million yuan for 2025, compared to a loss of 26.77 million yuan in the previous year [15] - Qitian Technology expects a loss of 60 to 95 million yuan for 2025, an improvement from a loss of 214 million yuan in the previous year [16] - Sanyuan Gene announced a plan to reduce its shareholding by up to 2% [17] Group 6 - Zhongxing Junye forecasts a net profit increase of 134.32% to 173.37% for 2025, with expected profits between 300 million and 350 million yuan [18] - Shengshi Technology anticipates a net profit decrease of 50.26% to 64.55% for 2025, projecting profits between 62 million and 87 million yuan [19] - Lante Optical expects a net profit increase of 70.04% to 81.38% for 2025, with projected profits between 375 million and 400 million yuan [20] Group 7 - Dongfang Risen anticipates a loss of 2.3 to 2.9 billion yuan for 2025, compared to a loss of 3.436 billion yuan in the previous year [21] - Wandong Medical announced a change in leadership, electing Wang Jianguo as the new chairman [22] - Longsoft Technology expects a loss of 49 to 60 million yuan for 2025, with projected revenues between 148 million and 164 million yuan [23] Group 8 - Zongyi Co. forecasts a net profit increase of approximately 264.05% for 2025, with expected revenues of around 480 million yuan [24] - Sifang New Materials anticipates a loss of around 300 million yuan for 2025, with projected revenues of about 1 billion yuan [25] - Jiuding New Materials plans to acquire 100% of Jiuding New Energy for 39.51 million yuan [26] Group 9 - Kangyuan Pharmaceutical received approval for clinical trials of a new drug aimed at treating children's ailments [27] - Kaipu Testing announced plans for share reductions by its chairman and vice president [28] - Fengfan Co. intends to acquire 51% of Yanling Jiaye for 382.5 million yuan, with performance commitments for the next three years [29][30] Group 10 - Axin Security received a government subsidy of 6.8 million yuan [31] - Ge Microelectronics announced plans for a share reduction by a major shareholder [32] - ST Yingfit expects a loss of 24 to 31 million yuan for 2025, a reduction from a loss of 40.4 million yuan in the previous year [33] Group 11 - Fujilai forecasts a net profit increase of 282.17% to 296.8% for 2025, with expected profits between 62.7 million and 65.1 million yuan [34] - Huakong Saige anticipates a loss of 97 to 120 million yuan for 2025, a shift from a profit of 17.03 million yuan in the previous year [35] - Landun Optical expects a loss of 70 to 95 million yuan for 2025, compared to a profit of 6.49 million yuan in the previous year [36] Group 12 - ST Zhongji forecasts a loss of 35 to 55 million yuan for 2025, compared to a loss of 231 million yuan in the previous year [37] - Zhongsheng Pharmaceutical expects a profit of 260 to 310 million yuan for 2025, reversing a loss of 299 million yuan in the previous year [38] - Youkeshu reported a net loss of 13.85 million yuan for the first three quarters of 2025 [39] Group 13 - Haosheng Electronics anticipates a net profit decrease of 56.85% to 59.77% for 2025, projecting profits between 69 million and 74 million yuan [40] - Xiangyuan Cultural Tourism plans to withdraw from a low-altitude economic investment fund [41] - Guoen Co. has set a preliminary price range of 34 to 42 HKD for its H-share issuance [42]

Summary of Zhongxing Junye (002772.SZ) 2025 Annual Performance Forecast Company Overview - **Company**: Zhongxing Junye (002772.SZ) - **Industry**: Agriculture, specifically mushroom cultivation Key Financial Metrics - **Net Profit Attributable to Shareholders**: - Forecasted range: 300 million to 350 million CNY - Year-on-year growth: 134.32% to 173.37% [1] - **Net Profit Excluding Non-Recurring Gains and Losses**: - Forecasted range: 268.5 million to 318.5 million CNY - Year-on-year growth: 192.57% to 247.06% [2] Core Reasons for Significant Growth - **Sales Performance**: - The sales price of Agaricus bisporus (common mushroom) has remained stable with an upward trend [3] - **Production Capacity**: - The Hubei Zhongxing base is operating at full capacity, contributing to increased sales and profitability [4] Additional Important Insights - The substantial growth in net profit is attributed to both price stability and increased production capacity, indicating a strong market position and operational efficiency [5]

Core Viewpoint - Tianshui Zhongxing Mushroom Industry Co., Ltd. (referred to as "Zhongxing Mushroom") expects significant profit growth for the fiscal year 2025, driven by rising product prices and increased production capacity [1][2] Financial Performance - The company anticipates a net profit attributable to shareholders of 300 million to 350 million yuan, representing a year-on-year increase of 134.32% to 173.37% [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between 269 million and 319 million yuan, reflecting a year-on-year growth of 192.57% to 247.06% [1] - Financial expenses are expected to decrease by approximately 20 million yuan due to changes in market interest rates, exchange rates, and interest capitalization [1] Business Strategy and Development - Zhongxing Mushroom focuses on the research, cultivation, and sales of edible and medicinal fungi, with leading production capacities for enoki mushrooms and button mushrooms [1] - The company has established production bases in multiple provinces, including Gansu, Shaanxi, Shandong, Jiangsu, Henan, Sichuan, Anhui, and Hubei [1] - In 2025, the company plans to diversify its business by advancing the industrialization of Cordyceps sinensis and other rare edible and medicinal fungi [1][2] Investment Projects - In June 2025, Zhongxing Mushroom signed investment agreements to establish Sichuan Zhongxing Mushroom Technology Co., Ltd. with an investment of 700 million yuan for a "Southwest Headquarters Base Project" focused on the industrialization of Cordyceps sinensis [2] - The wholly-owned subsidiary, Tianshui Zhong'an Biotechnology Co., Ltd., will also shift its production focus to the industrialization of Cordyceps sinensis [2] - Another subsidiary, Meishan Changhong Agricultural Biotechnology Co., Ltd., will implement technological upgrades starting May 2024 to explore the research and cultivation of rare edible and medicinal fungi [2]